retatrutide phase 2 weight loss results VisualAbstract: reduces body by 17.5% in patients with obesity New Phase 3 retatrutide data
Description
[DOI] [PMC free article] [PubMed] [Google Scholar] 151.Liskiewicz A, Khalil A, Liskiewicz D, et al
In Phase 2 clinical trials, 88.8% of patients successfully tolerated treatment through 48 weeks
They follow total fat and lean mass changes over time using DEXA (dual-energy X-ray absorptiometry) scans
However, further adequately powered studies are needed to directly compare this approach with medication withholding
Vadodaria to ensure proper recovery
Tirzepatide has shown even greater efficacy, with some patients losing up to 20% of their body weight
